These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1374262)

  • 1. Human therapeutics based on triple helix technology.
    Chubb JM; Hogan ME
    Trends Biotechnol; 1992 Apr; 10(4):132-6. PubMed ID: 1374262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing the influence of stereoelectronic effects on the biophysical properties of oligonucleotides: comprehensive analysis of the RNA affinity, nuclease resistance, and crystal structure of ten 2'-O-ribonucleic acid modifications.
    Egli M; Minasov G; Tereshko V; Pallan PS; Teplova M; Inamati GB; Lesnik EA; Owens SR; Ross BS; Prakash TP; Manoharan M
    Biochemistry; 2005 Jun; 44(25):9045-57. PubMed ID: 15966728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
    Arimondo PB; Bailly C; Boutorine AS; Moreau P; Prudhomme M; Sun JS; Garestier T; Hélène C
    Bioconjug Chem; 2001; 12(4):501-9. PubMed ID: 11459453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress toward oligonucleotide therapeutics: pharmacodynamic properties.
    Crooke ST
    FASEB J; 1993 Apr; 7(6):533-9. PubMed ID: 7682523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.
    Carbone GM; McGuffie E; Napoli S; Flanagan CE; Dembech C; Negri U; Arcamone F; Capobianco ML; Catapano CV
    Nucleic Acids Res; 2004; 32(8):2396-410. PubMed ID: 15121897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shape space. Is biopharmaceutical discovery entering a new evolutionary stage?
    Edgington SM
    Biotechnology (N Y); 1993 Mar; 11(3):285-9. PubMed ID: 7680208
    [No Abstract]   [Full Text] [Related]  

  • 8. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides.
    Hélène C
    Anticancer Drug Des; 1991 Dec; 6(6):569-84. PubMed ID: 1772570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA.
    Volkmann S; Jendis J; Frauendorf A; Moelling K
    Nucleic Acids Res; 1995 Apr; 23(7):1204-12. PubMed ID: 7537875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Oligonucleotides Internally Labeled with Peptides Show Improved Target Recognition and Stability to Enzymatic Degradation.
    Taskova M; Madsen CS; Jensen KJ; Hansen LH; Vester B; Astakhova K
    Bioconjug Chem; 2017 Mar; 28(3):768-774. PubMed ID: 28292178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational and combinatorial strategies for designing oligonucleotides targeted to RNA structures.
    Toulmé JJ; Le Tinévez R; Boiziau C; Dausse E
    Nucleic Acids Symp Ser; 1997; (36):39-41. PubMed ID: 9478200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence-specific recognition of double helical RNA and RNA.DNA by triple helix formation.
    Han H; Dervan PB
    Proc Natl Acad Sci U S A; 1993 May; 90(9):3806-10. PubMed ID: 7683407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM
    Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter.
    Blume SW; Gee JE; Shrestha K; Miller DM
    Nucleic Acids Res; 1992 Apr; 20(7):1777-84. PubMed ID: 1579471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-independent and linear variation of oligonucleotide DNA binding stabilities.
    Hoheisel JD
    Nucleic Acids Res; 1996 Feb; 24(3):430-2. PubMed ID: 8602354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The polypurine tract, PPT, of HIV as target for antisense and triple-helix-forming oligonucleotides.
    Volkmann S; Dannull J; Moelling K
    Biochimie; 1993; 75(1-2):71-8. PubMed ID: 7684936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The triple helix: a potential mechanism for gene regulation.
    Minton KW
    J Exp Pathol; 1985; 2(3):135-48. PubMed ID: 2431114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a triple-helix-specific cleaving reagent.
    Zain R; Marchand C; Sun J; Nguyen CH; Bisagni E; Garestier T; Hélène C
    Chem Biol; 1999 Nov; 6(11):771-7. PubMed ID: 10574778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.